Report Overview

The global Immunomodulators market was pegged at US$ 191.23 billion in 2021 and is expected to witness a CAGR of 5.3% during the forecast period.

Market Fundamentals

 Immunomodulators are the type of medications that either stimulate or repress the immune system, affect the immune system, and change the immunological response. These medications lessen the development of antibodies that trigger immunological responses in response to foreign antigens. Immunomodulators are substances that both depress the immune system and stimulate it.

[856756546]

Market Dynamic

The factors contributing to the growth of the global immunomodulators market is the rising incidence of chronic diseases such as asthma, cancer, allergic illnesses, and multiple sclerosis etc. Additionally, it is projected that the global immunomodulators market would rise as early immunomodulator therapy becomes more widely used to treat Crohn's disease. In addition, the market expansion is being fueled by the significant unmet clinical needs for the treatment of immunological illnesses such as rheumatoid arthritis. Due to the limited options, which are limited to TNF inhibitors, there is an increasing demand for alternative treatments for rheumatoid arthritis, which is anticipated to create attractive growth possibilities for the immunomodulators market.

However, the stringent government regulations in the process of approval for immunomodulators are the major challenge to the growth of the global immunomodulators market. 

Market Ecosystem

The global Immunomodulators market has been analyzed from three perspectives: product, application, and region.

Immunomodulators Market by Product

[98977686]

Based on the product, the global immunomodulators market has been divided into Immunostimulants and Immunosuppressants. The immunostimulants segment is further divided into antibodies, vaccines, and others, and the immunosuppressants segment is further divided into antimetabolites, antibodies, calcineurin inhibitors, glucocorticoids, and others. The immunosuppressants segment dominates the global immunomodulators market due to the extensive range of treatments that are currently accessible, including azathioprine, cyclosporine, corticosteroids, and monoclonal antibodies. These medications are used to suppress the immune response to prevent organ transplant rejection, including kidney, heart, and liver transplants. The high applicability of immunosuppressant medications in the treatment of numerous autoimmune disorders, such as psoriasis, alopecia areata, and lupus, among others, is providing this market with greater growth potential in addition to the presence of a large product range.

Immunomodulators Market by Application

Based on the application, the global Immunomodulators market is subdivided into respiratory, multiple sclerosis, HIV, and others. The multiple sclerosis segment holds the dominant position in the global immunomodulators market. This is due to the widespread use of immunomodulators in the treatment. It is projected that the anticipated introduction of immunomodulatory treatments for the treatment of multiple sclerosis would be the main factor driving the growth of this segment.

Immunomodulators Market by Region

Based on region, the global Immunomodulators market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. The global market for immunomodulators is dominated by North America. The prevalence of a sizable ill population in this area is responsible for this domination. The immunomodulators market is expected to be driven by the rising end-user demand for immunomodulator-based treatments and the high therapy costs related to treating multiple sclerosis with these immunotherapeutic drugs. The availability of encouraging government programs and higher end-user knowledge levels are also contributing to the high demand for immunomodulators.

Competitive Landscape

Some of the prominent players operating in the global immunomodulators market are: - 

• Eli Lilly and Company
• Merck & Co., Inc.
• Biogen
• F. Hoffmann-La Roche Ltd.
• Amgen, Inc.
• Johnson & Johnson
• Abbott Laboratories
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers & Squibb Company

Strategic Developments

• In June 2022, Eli Lilly and Company and Incyte announced the approval of its drug OLUMIANT® (baricitinib), by FDA. It has been approved for the treatment of alopecia areata. 

Frequently Asked Questions About This Report